Committed to Science and Teamwork
MIRA brings together leading scientists, doctors, researchers and business executives.
MIRA-ing Neuroscientific Breakthroughs
MIRA Pharmaceuticals, Inc. (MIRA) is a preclinical-stage pharmaceutical development company with two neuroscientific programs targeting a broad range of neurologic and neuropsychiatric disorders. The Company’s novel oral pharmaceutical marijuana, MIRA-55, is currently being developed to treat adult patients suffering from neuropathic pain, anxiety and cognitive decline, often associated with early-stage dementia. We have an exclusive licensing agreement for Ketamir-2 (“Ketamir”), a unique, patent-pending novel oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).
Introducing MIRA-55
Our Key Candidate
If approved by the FDA, our initial drug candidate, MIRA-55, may be a significant advancement in treating neuropsychiatric, inflammatory, and neurologic diseases and disorders. MIRA-55 unlocks the therapeutic potential of marijuana with a single molecule that targets binding sites of the body’s endocannabinoid system.
Learn About MIRA-55Introducing Ketamir
Our secondary drug candidate is a unique, patent pending novel ketamine analog that is predicted to have good gastrointestinal bioavailability. It is currently under investigation to potentially orally deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).
Learn About KetamirMeet Our Scientific Advisory Board
We continue to add clinical and scientific talent to our research and discovery team to evaluate our research, advise us on new processes and support our science.
View Our Scientific Advisory Board